{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:17:14Z","timestamp":1747199834668,"version":"3.40.5"},"reference-count":15,"publisher":"Zhejiang University Press","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1631\/jzus.b2300835","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T14:42:44Z","timestamp":1724337764000},"page":"719-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Waldenstr\u00f6m macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy","\u534e\u6c0f\u5de8\u7403\u86cb\u767d\u8840\u75c7: \u6297 CD19 \u5d4c\u5408\u6297\u539f\u53d7\u4f53 T \u7ec6\u80de\u7597\u6cd5\u6cbb\u7597\u7684\u6311\u6218\u6027\u75c5\u4f8b"],"prefix":"10.1631","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-6226","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3600-3784","authenticated-orcid":false,"given":"Xiaolin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-3804","authenticated-orcid":false,"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"8","key":"767_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/ajh.26210","volume":"96","author":"JP Abeykoon","year":"2021","unstructured":"Abeykoon JP, Zanwar S, Ansell SM, et al., 2021. Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia. Am J Hematol, 96(8):945\u2013953. https:\/\/doi.org\/10.1002\/ajh.26210","journal-title":"Am J Hematol"},{"issue":"2","key":"767_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/10428194.2019.1665668","volume":"61","author":"R Bansal","year":"2020","unstructured":"Bansal R, Jurcic JG, Sawas A, et al., 2020. Chimeric antigen receptor T cells for treatment of transformed Waldenstr\u00f6m macroglobulinemia. Leuk Lymphoma, 61(2):465\u2013468. https:\/\/doi.org\/10.1080\/10428194.2019.1665668","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"767_CR3","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","volume":"4","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Meid K, Flynn CA, et al., 2020. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up. Blood Adv, 4(16):3952\u20133959. https:\/\/doi.org\/10.1182\/bloodadvances.2020001963","journal-title":"Blood Adv"},{"issue":"1","key":"767_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.21.01194","volume":"40","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Allan JN, Siddiqi T, et al., 2022. Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia. J Clin Oncol, 40(1):63\u201371. https:\/\/doi.org\/10.1200\/JCO.21.01194","journal-title":"J Clin Oncol"},{"issue":"2","key":"767_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.26796","volume":"98","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, 2023. Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol, 98(2):348\u2013358. https:\/\/doi.org\/10.1002\/ajh.26796","journal-title":"Am J Hematol"},{"issue":"11","key":"767_CR6","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","volume":"33","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A, et al., 2019. A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia, 33(11):2654\u20132661. https:\/\/doi.org\/10.1038\/s41375-019-0431-y","journal-title":"Leukemia"},{"issue":"5","key":"767_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.hoc.2018.05.013","volume":"32","author":"C Kyriakou","year":"2018","unstructured":"Kyriakou C, 2018. High-dose therapy and hematopoietic stem cell transplantation in Waldenstr\u00f6m macroglobulinemia. Hematol Oncol Clin North Am, 32(5):865\u2013874. https:\/\/doi.org\/10.1016\/j.hoc.2018.05.013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"767_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al., 2019. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol, 20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"2","key":"767_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, et al., 2003. Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol, 30(2):110\u2013115. https:\/\/doi.org\/10.1053\/sonc.2003.50082","journal-title":"Semin Oncol"},{"issue":"2","key":"767_CR10","doi-asserted-by":"publisher","first-page":"e004128","DOI":"10.1136\/jitc-2021-004128","volume":"10","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Qualls D, Monette S, et al., 2022. CD19-directed chimeric antigen receptor T cell therapy in Waldenstr\u00f6m macroglobulinemia: a preclinical model and initial clinical experience. J Immunother Cancer, 10(2):e004128. https:\/\/doi.org\/10.1136\/jitc-2021-004128","journal-title":"J Immunother Cancer"},{"issue":"12","key":"767_CR11","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1080\/10428194.2020.1789625","volume":"61","author":"G Ruan","year":"2020","unstructured":"Ruan G, Zanwar S, Abeykoon JP, et al., 2020. Predictors of short-term survival in Waldenstr\u00f6m macroglobulinemia. Leuk Lymphoma, 61(12):2975\u20132979. https:\/\/doi.org\/10.1080\/10428194.2020.1789625","journal-title":"Leuk Lymphoma"},{"issue":"S3","key":"767_CR12","doi-asserted-by":"publisher","first-page":"e68877ca","DOI":"10.1097\/01.HS9.0000971284.68877.ca","volume":"7","author":"M Shadman","year":"2023","unstructured":"Shadman M, Yeung C, Redman MW, et al., 2023. CD20 CART therapy with MB-106 for BTK inhibitor-refractory Waldenstr\u00f6m macroglobulinemia (WM)\/lymphoplasmacytic lymphoma (LPL) - single institution study. HemaSphere, 7(S3):e68877ca. https:\/\/doi.org\/10.1097\/01.HS9.0000971284.68877.ca","journal-title":"HemaSphere"},{"issue":"26","key":"767_CR13","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/blood.2023020240","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Tam CS, 2023. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood, 141(26):3137\u20133142. https:\/\/doi.org\/10.1182\/blood.2023020240","journal-title":"Blood"},{"issue":"6","key":"767_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","volume":"126","author":"SP Treon","year":"2015","unstructured":"Treon SP, 2015. How I treat Waldenstr\u00f6m macroglobulinemia. Blood, 126(6):721\u2013732. https:\/\/doi.org\/10.1182\/blood-2015-01-553974","journal-title":"Blood"},{"issue":"2","key":"767_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","volume":"60","author":"SP Treon","year":"2023","unstructured":"Treon SP, Tedeschi A, San-Miguel J, et al., 2023. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom\u2019s macroglobulinemia on diagnostic and response criteria. Semin Hematol, 60(2):97\u2013106. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.009","journal-title":"Semin Hematol"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2300835\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:04:48Z","timestamp":1724403888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2300835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2300835","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"type":"print","value":"1673-1581"},{"type":"electronic","value":"1862-1783"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yang YANG, Xiaolin GU, Jingsong HE, Yongxian HU, and Zhen CAI declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"Our study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University (No. 20230720A). All procedures followed were in accordance with the ethical standards of the responsible committee on humanexperimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2013. Informed consent was obtained from the patient for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}